Navigation Links
Tengion Appoints Jeff Randall to Board of Directors
Date:2/27/2008

EAST NORRITON, Pa., Feb. 27 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that it has appointed Jeff Randall to its Board of Directors. Mr. Randall brings more than 25 years experience as a senior- level executive, CFO and CEO at public and private companies to Tengion, including expertise in the healthcare, device manufacturing and electronics industries.

"We are pleased to welcome Jeff to the Tengion Board of Directors," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "His expertise in developing the financial infrastructure for biotech companies will be a valuable addition to our Board and we look forward to working with him."

Mr. Randall's career has included serving as CFO at seven companies, three of which then appointed him to the post of CEO. Now a financial consultant, he most previously held management team positions at Eximias Pharmaceutical Corporation and i-STAT Corporation and has extensive experience working with and serving on Boards of Directors. Mr. Randall received his B.S. from The Pennsylvania State University, his M.B.A. from Northeastern University and served in the U.S. Air Force.

"Tengion's technology and the strength of its management team and Board of Directors made this an exciting opportunity," said Mr. Randall. "I am looking forward to working with the company and my fellow members of the Board to realize Tengion's potential and help the company achieve its corporate goals."

About Tengion

Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform(TM) that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure - rather than treat - organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
4. Codexis Appoints Singapore Laboratories Managing Director
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. NeurogesX Appoints New Director to the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... CARLOS, Calif. , Jan. 23, 2017 /PRNewswire/ ... developing innovative treatments for neurodegenerative diseases and other ... has joined the company as Chief Medical Officer. ... translational and clinical development activities at Alkahest and ... Dr. Jackson most recently served as Executive Director ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port business ... Wistar Institute, and Sanguis, launched by a trio of students from the University of ... developing a treatment for a chronic viral infection and its associated diseases, with the ...
Breaking Biology Technology:
(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
Breaking Biology News(10 mins):